REGENXBIO Inc., a gene therapy company, plans to sell $175 million of its common stock in an underwritten public offering.
The Rockville, Md.-based company said underwriters will have an option to buy up to an additional 15% of the common shares sold under the offer.
Morgan Stanley, Bank of America Merrill Lynch and Barclays are acting as joint book-running managers. Raymond James is acting as co-manager of the offering.
Regenxbio uses its NAV technology platform, an adeno-associated virus gene delivery platform, to engineer product candidates for treatment of retinal, metabolic and neurodegenerative diseases.